UPDATE ON THE SAHPRA REVIEW OF THE SPUTNIK V VACCINE

18 October 2021

SAHPRA has been engaged in a rolling review of the data for the Sputnik V COVID-19 vaccine since the initial application was submitted on 23 February 2021. This vaccine was developed by the Gamaleya Research Institute of Epidemiology and Microbiology in the Russian Federation. The locally-licensed applicant is Lamar International Pty (Ltd).

The Sputnik V vaccine combines two separate adenovirus-vectored constructs, one relying on the Adenovirus Type 26 (Ad26) and the other on Adenovirus Type 5 (Ad5), as the delivery vehicles for the antigen.

Download full statement